Role of ChatGPT in Vestibular Schwannoma Management

January 11, 2026 updated by: Janet Choi, University of Southern California
Previous studies have demonstrated that patients frequently undergo significant decision conflict regarding major medical decisions in otolaryngology. There lack validated tools available for decision support for patients. While limited evidence has demonstrated that clinical decision support tools can alleviate decision conflict for patients with diagnosis in otolaryngology, conversational language models were not employed in these studies and may provide additional benefit in this context. This study seeks to evaluate the efficacy of using ChatGPT, a conversational language model with basic clinical knowledge, in alleviating decision conflict for patients with new diagnosis in otolaryngology. For this pilot study, vestibular schwannoma, a benign tumor that develops on the vestibular nerve with known clinical equipoise, has been chosen for the initial study diagnosis. Efficacy will be evaluated by comparison of responses to the Decisional Conflict Scale (DCS) and Satisfaction with Decision (SWD) scores between a group given training in ChatGPT and a control group (no ChatGPT training).

Study Overview

Status

Withdrawn

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • 18 years or older
  • Diagnosed with vestibular schwannoma
  • Have access to internet-enabled device that is compatible with ChatGPT

Exclusion Criteria:

  • < 18 years old
  • patient without diagnosis of vestibular schwannoma
  • patient does not have access to internet-enabled device
  • patient who declines study participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Intervention with 1 week use of ChatGPT
Behavioral: Use of chatGPT for 1 week
Use of chatGPT for 1 week
Active Comparator: Delayed control
No ChatGPT use for 1 week and intervention after 1 week
Behavioral: Use of chatGPT for 1 week
Use of chatGPT for 1 week

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in scores of Decisional Conflict Scale after ChatGPT use
Time Frame: baseline, 1 week follow up, 2 week follow up
The Decisional Conflict Scale (DCS) measures 5 dimensions of decision making (feeling: uncertain, uninformed, unclear about values, unsupported; ineffective decision making). 15-item validated questionnaire. Score range 5-75 (higher score corresponding to higher levels of conflict in decision making)
baseline, 1 week follow up, 2 week follow up
Changes in scores of Satisfaction with Decision after ChatGPT use
Time Frame: baseline, 1 week follow up, 2 week follow up
The Satisfaction with Decision (SWD) scale measures satisfaction with health care decisions. 6-item validated questionnaire. Score range 5-30 (higher score corresponding to higher levels of satisfaction with decision)
baseline, 1 week follow up, 2 week follow up
Changes in scores for Knowledge on vestibular schwannoma management after ChatGPT use
Time Frame: baseline, 1 week follow up, 2 week follow up
4-item questionnaire (Likert scale) assessing participants' confidence in understanding the diagnosis and treatment options for vestibular schwannoma. Score range 5-20 (higher score corresponding to higher levels of confidence in understanding diagnosis and management of vestibular schwannoma)
baseline, 1 week follow up, 2 week follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

November 30, 2027

Study Registration Dates

First Submitted

October 24, 2023

First Submitted That Met QC Criteria

November 30, 2023

First Posted (Actual)

December 11, 2023

Study Record Updates

Last Update Posted (Actual)

January 13, 2026

Last Update Submitted That Met QC Criteria

January 11, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UP-23-00541

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vestibular Schwannoma

Clinical Trials on Use of chatGPT for 1 week

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe